Latest News and Press Releases

Oxford, UK and Boston, MA – November 13, 2025 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune...

Preclinical data highlight that PKM2 modulation inhibits several important mechanisms underlying atopic dermatitis pathologySYX-5219 is a first-in-class oral PKM2 modulator designed to drive...

Preclinical data highlight MTHFD2 as a promising metabolic target in autoimmune disease, providing strong validation for the advancement of SIT-047, Sitryx’s MTHFD2 inhibitor program, into clinical...

Dublin, Oct. 16, 2025 (GLOBE NEWSWIRE) -- The "OX40 Targeted Therapies Clinical Trials, Therapeutic Approaches, Proprietary Technology Platforms & Market Opportunity Insight 2026" report has...

Oxford, UK and Boston, MA – October 15, 2025 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune...

Tr1X announced the FDA has cleared its IND application for TRX319 in progressive multiple sclerosis and a $50M financing that extends its runway into 2027.

SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease remission across a range of autoimmune diseasesPhase 1b trial to investigate the safety, tolerability and initial...

Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK...

Positive top-line results for VIBRANT Phase 2 clinical trial of verekitug in CRSwNP with once every 12 week dosing

Upstream Bio to Host Conference Call/Webcast to Report Top-Line Data from Phase 2 VIBRANT Trial of Verekitug in Patients with CRSwNP